Literature DB >> 24490034

Targeting hypoxia in the leukemia microenvironment.

Juliana Benito1, Zhihong Zeng1, Marina Konopleva2, William R Wilson3.   

Abstract

The bone marrow (BM) microenvironment regulates survival and maintenance of normal hematopoietic stem cells. Within the endosteal niche, hypoxia has an essential role in maintenance of the primitive quiescent hematopoietic stem cell. We and others have demonstrated that in the context of hematologic malignancies the BM is highly hypoxic, and that progression of the disease is associated with expansion of hypoxic niches and stabilization of the oncogenic HIF-1α. This review will provide an overview of the normal and leukemic BM microenvironment with a special emphasis on pathological hypoxia including the development of hypoxia-activated prodrugs and their applicability in hematological malignancies.

Entities:  

Year:  2013        PMID: 24490034      PMCID: PMC3905090          DOI: 10.2217/IJH.13.32

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN: 2045-1393


  88 in total

1.  Characterization of perceived hyperoxia in isolated primary cardiac fibroblasts and in the reoxygenated heart.

Authors:  Sashwati Roy; Savita Khanna; William A Wallace; Jani Lappalainen; Cameron Rink; Arturo J Cardounel; Jay L Zweier; Chandan K Sen
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

2.  Quantitative determination of localized tissue oxygen concentration in vivo by two-photon excitation phosphorescence lifetime measurements.

Authors:  Egbert G Mik; Ton G van Leeuwen; Nicolaas J Raat; Can Ince
Journal:  J Appl Physiol (1985)       Date:  2004-07-09

3.  Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment.

Authors:  Faiyaz Notta; Sergei Doulatov; Elisa Laurenti; Armando Poeppl; Igor Jurisica; John E Dick
Journal:  Science       Date:  2011-07-08       Impact factor: 47.728

4.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

5.  In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche.

Authors:  Joji Fujisaki; Juwell Wu; Alicia L Carlson; Lev Silberstein; Prabhakar Putheti; Rafael Larocca; Wenda Gao; Toshiki I Saito; Cristina Lo Celso; Hitoshi Tsuyuzaki; Tatsuyuki Sato; Daniel Côté; Megan Sykes; Terry B Strom; David T Scadden; Charles P Lin
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

Review 6.  Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.

Authors:  William A Denny
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

Review 7.  Temperature correction of blood gas values.

Authors:  B A Shapiro
Journal:  Respir Care Clin N Am       Date:  1995-09

8.  A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Authors:  Michael B Jameson; Danny Rischin; Mark Pegram; John Gutheil; Adam V Patterson; William A Denny; William R Wilson
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-10       Impact factor: 3.333

9.  Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Authors:  Jian-Xin Duan; Hailong Jiao; Jacob Kaizerman; Timothy Stanton; James W Evans; Leslie Lan; Gustavo Lorente; Monica Banica; Don Jung; Jinwei Wang; Huaiyu Ma; Xiaoming Li; Zhijian Yang; Robert M Hoffman; W Steve Ammons; Charles P Hart; Mark Matteucci
Journal:  J Med Chem       Date:  2008-02-08       Impact factor: 7.446

10.  Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

Authors:  Juliana Benito; Yuexi Shi; Barbara Szymanska; Hernan Carol; Ingrid Boehm; Hongbo Lu; Sergej Konoplev; Wendy Fang; Patrick A Zweidler-McKay; Dario Campana; Gautam Borthakur; Carlos Bueso-Ramos; Elizabeth Shpall; Deborah A Thomas; Craig T Jordan; Hagop Kantarjian; William R Wilson; Richard Lock; Michael Andreeff; Marina Konopleva
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

View more
  18 in total

Review 1.  Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles.

Authors:  Francesca Pistollato; Susanne Bremer-Hoffmann; Giuseppe Basso; Sandra Sumalla Cano; Iñaki Elio; Manuel Masias Vergara; Francesca Giampieri; Maurizio Battino
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

2.  A look back at 2016 in International Journal of Hematologic Oncology.

Authors:  Sebastian Dennis-Beron
Journal:  Int J Hematol Oncol       Date:  2017-05-18

3.  Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

Authors:  D I Staquicini; S D'Angelo; F Ferrara; K Karjalainen; G Sharma; T L Smith; C A Tarleton; D E Jaalouk; A Kuniyasu; W B Baze; B K Chaffee; P W Hanley; K F Barnhart; E Koivunen; S Marchiò; R L Sidman; J E Cortes; H M Kantarjian; W Arap; R Pasqualini
Journal:  Pharmacogenomics J       Date:  2017-12-05       Impact factor: 3.550

4.  WNT16-expressing Acute Lymphoblastic Leukemia Cells are Sensitive to Autophagy Inhibitors after ER Stress Induction.

Authors:  Meletios Verras; Ioanna Papandreou; Nicholas C Denko
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

5.  Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.

Authors:  Juliana Benito; Marc S Ramirez; Niki Zacharias Millward; Juliana Velez; Karine G Harutyunyan; Hongbo Lu; Yue-Xi Shi; Polina Matre; Rodrigo Jacamo; Helen Ma; Sergej Konoplev; Teresa McQueen; Andrei Volgin; Marina Protopopova; Hong Mu; Jaehyuk Lee; Pratip K Bhattacharya; Joseph R Marszalek; R Eric Davis; James A Bankson; Jorge E Cortes; Charles P Hart; Michael Andreeff; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2015-11-24       Impact factor: 12.531

6.  Oxygen tension variation in ischemic gastrocnemius muscle, marrow, and different hypoxic conditions in vitro.

Authors:  Ying Huang; Bing Chen; Jian Zhang
Journal:  Med Sci Monit       Date:  2014-11-05

7.  Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.

Authors:  Jessica D Sun; Qian Liu; Dharmendra Ahluwalia; Wenwu Li; Fanying Meng; Yan Wang; Deepthi Bhupathi; Ayesha S Ruprell; Charles P Hart
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.

Authors:  Silvia Bono; Matteo Lulli; Vito Giuseppe D'Agostino; Federico Di Gesualdo; Rosa Loffredo; Maria Grazia Cipolleschi; Alessandro Provenzani; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Oncotarget       Date:  2016-12-20

9.  DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.

Authors:  Alessia Stornetta; Peter W Villalta; Frederike Gossner; William R Wilson; Silvia Balbo; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2017-02-19       Impact factor: 3.739

Review 10.  Hypoxia and Hypoxia-Inducible Factors in Leukemias.

Authors:  Margaux Deynoux; Nicola Sunter; Olivier Hérault; Frédéric Mazurier
Journal:  Front Oncol       Date:  2016-02-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.